Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in Real-World Treatment of Primary Liver Cancer
ChiCTR2000034264Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoints: Median progression-free survival (mPFS) and Median recurrence-free survival (RFS). Started Jun 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000034264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034264.